Current animal models of hemophilia: the state of the art by unknown
REVIEW Open Access
Current animal models of hemophilia:
the state of the art
Ching-Tzu Yen1,2, Meng-Ni Fan1, Yung-Li Yang3,4, Sheng-Chieh Chou5, I-Shing Yu6 and Shu-Wha Lin1,2,3*
From The 9th Congress of the Asian-Pacific Society on Thrombosis and Hemostasis
Taipei, Taiwan. 6-9 October 2016
Abstract
Hemophilia is the most well-known hereditary bleeding disorder, with an incidence of one in every 5000 to 30,000
males worldwide. The disease is treated by infusion of protein products on demand and as prophylaxis. Although
these therapies have been very successful, some challenging and unresolved tasks remain, such as reducing bleeding
rates, presence of target joints and/or established joint damage, eliminating the development of inhibitors, and increasing
the success rate of immune-tolerance induction (ITI). Many preclinical trials are carried out on animal models for
hemophilia generated by the hemophilia research community, which in turn enable prospective clinical trials
aiming to tackle these challenges. Suitable animal models are needed for greater advances in treating hemophilia, such
as the development of better models for evaluation of the efficacy and safety of long-acting products, more powerful
gene therapy vectors than are currently available, and successful ITI strategies. Mice, dogs, and pigs are the most
commonly used animal models for hemophilia. With the advent of the nuclease method for genome editing,
namely the CRISPR/Cas9 system, it is now possible to create animal models for hemophilia other than mice in
a short period of time. This review presents currently available animal models for hemophilia, and discusses the
importance of animal models for the development of better treatment options for hemophilia.
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Background
Hemophilia, caused by deficiency or dysfunction of coagu-
lation factor VIII (FVIII) or factor IX (FIX), is the most
well-known hereditary bleeding disorder, with an incidence
of one in every 5000 to 30,000 males worldwide. Current
standard care involves intravenous infusions of protein
products on demand, and prophylaxis. Although very suc-
cessful, protein replacement therapy runs the risk of indu-
cing neutralizing antibodies or “inhibitors”. Patients with
inhibitors can no longer use FVIII/FIX concentrates and
require more expensive bypass products [1] or elimination
of the inhibitors by immune-tolerance induction (ITI) [2].
ITI may not be performed due to economical accessibility
(affordability) of FVIII/FIX products and, in addition, ITI
of hemophilia-B is performed less often because inhibitors
are less well-developed and have lower success rates.
Multiple factors are involved in the success of ITI of
hemophilia A including the historical peak and pre-ITI
level of inhibitors, age of patients, time period from inhibi-
tor diagnosis to ITI, interruptions of ITI and peak inhi-
bitors during ITI. Products and regimen may also play a
role in ITI outcome, although current clinical data are
contradictory or inconclusive with regard to this point.
Considerable effort has been exerted to improve
hemophilia treatment through the development of long-
acting products, powerful gene therapy vectors, and suc-
cessful ITI strategies. Clinical trials aiming to tackle
these challenges have been undertaken, and many pre-
clinical trials have been carried out on animal models
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for hemophilia generated by the research community.
Preclinical and clinical trials all require a suitable animal
model of hemophilia. The most commonly used animal
models for hemophilia include but are not limited to
mice, dogs, and pigs. Animal models are important for
basic biological and preclinical studies, such as studies
aimed at understanding the pathophysiology of inhibitor
formation, improving ITI protocols, estimating drug
doses, and evaluating therapeutic efficacy before human
trials. With the advent of the nuclease method for gen-
ome editing, named the CRISPR/Cas9 system, it is now
possible to create animal models of hemophilia other
than mice in a short period of time. This review presents
an overview of currently available animal models for
hemophilia, and discusses the importance of animal
models for the development of better treatment options
for hemophilia.
Review
Hemophilia animals with spontaneous mutations
Hemophilia A dogs
Dogs with naturally occurring hemophilia A were first doc-
umented following observations of abnormally prolonged
bleeding that could be treated or prevented by infusion of
canine FVIII. Currently, two colonies of hemophilia A dogs
are most commonly used in studies: an Irish Setter colony
maintained at the University of North Carolina in Chapel
Hill [3], and a miniature schnauzer colony maintained at
Queens University in Toronto, Canada [4]. Both colonies
are deficient in circulating FVIII and show an aberrant
inversion mutation between ~0.5 Mb upstream of the
FVIII gene and its intron 22 [5, 6]. In addition to intron 22
inversion of FVIII gene, dogs with hemophilia A have also
been described to have other spontaneous mutations in the
FVIII gene [7, 8].
Hemophilia A dogs have been used extensively in pre-
clinical trials of human FVIII protein products as well as in
studies on the safety and efficacy of adeno-associated viral
(AAV) vector-conducted gene therapy [9], in testing the
gene therapy of platelet-specific expression of human FVIII
[10], and have provided promising data for bypass therapy
[11]. A subset of these dogs have a propensity to develop
inhibitors [12] after infusion of canine FVIII [13, 14], with
the Queens colony being more prone to inhibitor deve-
lopment than the Chapel Hill dogs. Dogs with inhibitors
can facilitate the studies of inhibitor pathogenesis and ITI
strategies, e.g., eradication of pre-existing neutralizing anti-
bodies by liver gene therapy [15]. The development of in-
hibitors to FVIII is the most significant complication of
protein replacement therapy. Because of the high hom-
ology of the canine and human immune system, assess-
ments of FVIII immunogenicity using hemophilia A dogs
may provide meaningful insights into the human immune
response.
Hemophilia A sheep
Phenotypes consistent with human hemophilia A, including
spontaneous bleeding and plasma FVIII activity of less than
1 %, have been found in sheep [16, 17]. Sheep with nat-
urally occurring hemophilia A were re-established through
reproductive technologies in 2009. Sequence mapping re-
vealed a single nucleotide insertion-induced frame shift of
the FVIII gene creating a premature stop codon at the base
position 3112–4 in exon 14 and five additional stop codons
within the next 183 bp [18]. Hemophilia sheep have been
used in studies relevant to gene and cell therapies for
hemophilia, including investigations of pre-existing immun-
ity to AAV vectors [19] and the use of mesenchymal stem
cells as cellular delivery vehicles for the FVIII gene [20].
However, the restricted availability of the recombinant
ovine FVIII for treatment may limit the practical use of
hemophiliac sheep.
Hemophilia A rats
Researchers identified an inbred WAG/RijY rat strain, des-
ignated WAG/RijYcb, which tended to show abnormal
hemorrhaging, a prolonged activated partial thromboplas-
tin time, and a mutated FVIII gene (proline was substituted
for leucine at amino acid 176 in the A1 domain). In rats,
the FVIII gene is located on chromosome 18. Thus,
hemophilia in rats is autosomal recessive, which contrasts
with humans and other animal models where it is an X-
linked hereditary disease [21, 22]. The mutated FVIII
region of WAG/RijYcb rats generally lacks immunodomi-
nant epitopes for inhibitor formation thus this model may
not be suitable for studying the immune response to FVIII
treatment or developing ITI strategies.
Hemophilia B dogs
Similar to human hemophilia B, canine hemophilia B has
a sex-linked inheritance pattern, and no detectable circu-
lating FIX exists in the plasma. Researchers have identified
at least three colonies of hemophilia B dogs, each of which
has a unique molecular FIX defect. Hemophilia B cairn
terriers were identified in Toronto [23] and have been
maintained in Chapel Hill since 1966 [24]. These animals
have a point mutation that results in substitution of glu-
tamic acid for glycine at AA 377 in the catalytic domain
[24]. Lhasa Apso dogs with hemophilia B, established in
Auburn, Alabama [25], carry a 5-bp deletion at nucleo-
tides 772–776 and a C-to-T transition in the FIX gene,
resulting in a premature stop codon at AA 146 [25]. A
Labrador retriever colony at Cornell University, New York
[26], carries complete deletion of the canine FIX gene.
Chapel Hill and Auburn dogs have been used extensively
for testing FIX products and gene therapy strategies. The
Auburn dogs are prone to developing inhibitors to infused
canine FIX [27, 28]. Translational data produced from
hemophilia B dogs have supported the development of
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long-acting FIX [29, 30] with accompanying recent human
clinical trials [12, 31–34]. In contrast to the higher success
ITI rate in hemophilia A, the ITI outcome in hemophilia
B patients with FIX inhibitors is poor and research in this
area remains in its infancy [35]. Recently, an ITI strategy
using AAV liver expression of a FIX variant, FIX-Padua
was successfully applied to hemophilia B dogs prone to in-
hibitors. This strategy eradicated FIX inhibitor in dogs
with pre-existing inhibitors [34], suggesting its value in
the development of ITI.
Genetically engineered animal models of hemophilia
Hemophilia A mice
As small mammals that are easy to breed and relatively
inexpensive to maintain in large numbers, mice are a
popular animal for medical research and preclinical test-
ing worldwide. Although spontaneous bleeding does not
naturally occur in mice, genome-editing technologies
have contributed to development of various hemophiliac
mouse models. Hemophilia mice are the best initial
model to use when attempting to test new therapeutics
because they only require small amounts of drugs.
In 1995, the first two hemophilia A mouse models,
with a mixed genetic background of 129SV and C57BL/
6, were established. These two strains of FVIII knockout
mice were generated through gene targeting and embry-
onic stem cell manipulation [36]. A neo cassette was
inserted into the 3′ end of exon 16 of the mouse FVIII
gene in one strain (E16 mice), whereas exon 17 was dis-
rupted in the other strain (E17 mice). Mice had no detect-
able circulating FVIII, and their plasma FVIII activity was
less than 1 %. Unlike human hemophilia A, little spontan-
eous bleeding is observed in mouse models of hemophilia
A, whereas tail clipping or other invasive procedures
could lead to death. Mouse models of hemophilia A are
widely used for the evaluation of FVIII treatment efficacy
[37, 38], investigation of mechanisms of inhibitor forma-
tion, and development of ITI protocols for FVIII [39].
To mimic patients with severe hemophilia A who ex-
press no endogenous FVIII (i.e., cross-reacting material)
and are prone to form inhibitors after protein replacement
therapy, researchers generated a total FVIII gene knockout
hemophilia A mouse model in a pure C57BL/6 back-
ground. The entire coding sequence was deleted by a Cre
recombinase-LoxP site-mediated deletion. Plasma FVIII
activity and anti-FVIII inhibitor titer induced after FVIII
treatment were comparable to those of E16 mice [40].
Hemophilia A pig
Pigs with hemophilia A were generated by nuclear transfer
and cloning from porcine fetal fibroblasts carrying disrup-
tion of exon 16 of the porcine FVIII gene by the neomycin-
resistant gene [41]. Species differences between humans
and mice, such as size, general physiology, anatomy, and
lifespan, limit the value of mouse models in preclinical tri-
als. In contrast, the coagulation systems of pigs and humans
are highly homologous. Moreover, hemophilia A pigs
may develop arthropathy similar to humans because of
repeated joint bleeding [41]. Thus, hemophilia A pigs
provide another option for evaluating novel therapeu-
tics for hemophilia A patients [42].
Hemophilia B mice
Although mice with naturally occurring deficiency of
FIX have not been identified, a series of FIX knockout
mice were engineered by homologous recombination in
embryonic stem cells. Initially, the mouse FIX gene was
disrupted by insertion of a neo cassette into exon 3 [43] or
the coding region for the catalytic domain of FIX [44, 45],
resulting in a mouse model with no detectable mRNA or
plasma protein expression of FIX. In addition to mice with
complete deletion of FIX, researchers have created knock-
in mice expressing human FIX carrying a missense muta-
tion (R333Q-hFIX) under the control of the mouse FIX
promoter. The R333Q mutation is located in the catalytic
domain of human FIX; the same mutation has been iden-
tified in several patients with severe hemophilia B. In
R333Q hFIX mice, mutant human FIX transcript and cir-
culating human FIX protein were detectable throughout
development, but the FIX protein activity was <1 % [46].
Similar to hemophilia A mice, hemophilia B mice do not
show spontaneous bleeding, but will bleed and die after
tail clipping unless the wound is cauterized. Hemophilia B
mice have been used to test the efficacy of FIX and FIX
variants, including those FIX variants with very high clot-
ting activities [47–52], as well as to evaluate the immunity
and safety of gene therapy [53–55].
Researchers have also established several knock-in
mice carrying a FIX variant coding for K5A in the Gla
domain of FIX [56], a full-length wild-type (WT) human
FIX coding sequence, and a FIX variant expressing FIX-
Triple containing 3 amino acid modifications [47]. The
K5A mutation impairs FIX binding to collagen type IV,
and these mice show a relatively mild bleeding pheno-
type [56]. The knock-in mice with complete human WT
and FIX-Triple FIX coding sequence exhibited clotting
activity of, respectively, nearly 5 and 50 % that of mouse
FIX, which was unexpected and was perhaps due to spe-
cies specificity of FVIII [47].
Humanized hemophilia A mice for FVIII immunity
To understand the regulation of antibody responses
against FVIII in hemophilia A, researchers modified the
hemophilia A mouse model to be “humanized” for HLA
class II antigen. Researchers crossed E17 mice with mice
expressing chimeric human-mouse HLA-DRB1*1501,
which is associated with an increased risk of inhibitor
development in humans [57]. Use of this humanized
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hemophilia A mouse model allowed identification of
immunodominant FVIII peptides that trigger inhibitor
formation, as well as the characterization of interactions
of T-cell receptors with disease-associated FVIII peptides
and MHC class II molecules [58].
Novel hemophilia NSG mouse models established by
CRISPR/Cas9 technology
A recent advance in genetic engineering technology pro-
vides a powerful tool to modify the genome in any living
species [59]. CRISPR (clustered regularly interspaced short
palindromic repeat)-associated RNA-guided endonuclease
Cas9, which was identified from the microbial adaptive
immune system [60], can be used to alter the mammalian
genome with high efficiency and precision. Recently, a re-
liable animal model for elucidating the humoral and cellu-
lar immune responses of patients to FVIII/FIX treatment
was developed. The CRISPR/Cas9 system and immunode-
ficient NSG mice (Nod/Scid-Il2γ−/−) were combined to
mutate the FVIII and FIX genes, generating hemophilia A/
B mice with the NSG background (HemoA/B-NSG mice).
Oligonucleotides of 20 residues serving as specific guiding
RNAs (gRNAs) were developed to target exon 1 of mouse
FVIII and FIX. The gRNA and CRISPR/Cas9 RNA were
microinjected into the NSG mouse zygotes to generate
founders. Four male founder mice were obtained, each
carrying a 1, 2 or 5-bp deletion in exon 1 of the FVIII
gene, resulting in a premature stop codon (Fig. 1a). Hep-
atic FVIII mRNA level of these mice was 50 % lower than
that of NSG mice (unpublished data), whereas their
plasma FVIII activity was dramatically decreased to be
comparable to that of hemophilia A mice with the 129SV/
C57BL/6J mixed genetic background [36]. Two male
founder mice were identified that had the same mutation,
i.e., carrying an 8-nucleotide deletion in exon 1 of the FIX
gene, which created a premature stop codon (Fig. 1b).
NSG mice are more acceptable than NOD/SCID mice for
transplanting with human hematopoietic cells and can,
therefore, be used for direct assessment of the human im-
mune response to FVIII/FIX treatment.
Conclusions
Translational research from hemophilia animal models
gives valuable information about safety and efficacy, and
guides design of human clinical trials. Despite their avail-
ability, hemophilia animal models have many potential
Fig. 1 Illustration of NSG male mouse with missense mutation in exon 1 of the mouse FVIII or FIX gene. Sequences of tail DNA derived from male
founders of hemophilia NSG mice are shown. a Four male founders carrying mutations in the FVIII gene were generated. Deletion of 1 bp (−1/G),
2 bp (−2/GC), and 5 bp (−5/GTGCA) in exon 1 created a premature stop codon at the 72, 38 and 37th AA residue of mouse FVIII, respectively.
b One male founder carried an −8/CACCTGAA deletion in the FIX gene, which resulted in a premature stop codon at the 30th AA residue of
mouse FIX
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disadvantages and limitations, including a short half-life of
human FVIII (in mice), differences in tissue tropism of
viral vectors compared to humans, and immune reactions
to human FVIII/FIX. Reducing inhibitor incidence and
elimination of inhibitors in hemophilia patients is a major
task that needs to be resolved. It is considered that the use
of different products and treatment protocols may be
involved in inhibitor production [61], but the possible
mechanism(s) is not fully understood. An appropriate hu-
manized animal model for the evaluation of different prod-
ucts, regimens, and ITI strategies is still lacking. CRISPR/
Cas9 technology is a very efficient method to generate
hemophilia in rare and difficult-to-breed mice. We believe
that our hemophilia NSG mice will be a very useful model
for studying the human immune response to therapeutics.
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